Dr. Pierre Kory and his colleagues at the Front Line COVID-19 Critical Care Alliance (FLCCC) are leading an effort to assess the effectiveness of ivermectin as a prophylactic against and treatment for COVID and to communicate to the public the mounting evidence of its efficacy. (Ivermectin is well known as an anti-parasitic, and millions of doses are distributed annually in complete safety.)
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
No comments:
Post a Comment